Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

With the emergence of various classes of blood glucose-lowering agents, choosing the
appropriate drug for each patient is emphasized in diabetes management. Among incretin …

Antibodies conjugated to bioactive compounds allow targeted delivery of therapeutics to cell
types of choice based on that antibody's specificity. Here we develop a new type of …

Hyperlipidemia plays a crucial role in the underlying pathogenesis of multiple
cardiovascular diseases (CVD), including coronary artery disease, peripheral arterial …

Peptide epitope tags offer a valuable means for detection and manipulation of protein
targets for which high quality detection reagents are not available. Most commonly used …

Diabetes mellitus (DM) is strongly associated with an increased risk of atherosclerotic
cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) was …

Obesity, type 2 diabetes, and the numerous associated metabolic co-morbidities are
growing global threats to public health. Despite recent progress in pharmacotherapies for …

Among the biological approaches to therapeutics, are the cells, such as CAR-T cells
engineered or not, the antibodies armed or not, and the smaller protein scaffolds that can be …

Fusion of a target-specific peptide to a full-length antibody (Ab) can result in a peptide–Ab
fusion protein with additional specificity and enhanced activity. We recently developed an …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a clinically validated target for
treating hypercholesterolemia. Peptide‐based PCSK9 inhibitors have attracted …